share_log

Chardan Capital Upgrades ProQR Therapeutics to Buy, Announces $2 Price Target

Benzinga ·  Nov 8, 2023 05:19

Chardan Capital analyst Keay Nakae upgrades ProQR Therapeutics (NASDAQ:PRQR) from Neutral to Buy and announces $2 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment